Medical Health & Life Science Research News

New report examines the engineered T cells market opportunity analysis and industry forecast, 2017-2023

Medical Market Research

The Global Engineered T Cells Market was valued at $146 million in 2016, and is estimated to reach at $2,124 million by 2023, registering a CAGR of 46.5% from 2017 to 2023. Engineered T cells are specifically altered T cells designed for the treatment of cancer.

Currently, these cells are being used for therapeutic and research purposes, which include tumor infiltrating lymphocytes, T cell receptor {TCR}, and chimeric antigen receptor {CAR}. Moreover, they are suitable to many types of cancers and overcome immunosuppressive tumor microenvironments, where T cells cannot detect tumor cells as a foreign object.

Furthermore, they help to reduce toxicities and restrict antigen escape (inability of immune system to respond to an infectious agent) for effective therapeutic actions.

The growth of the engineered T-cells market is driven by rise in prevalence of different types of cancers and surge in demand for biopharmaceutical therapies.

Moreover, advantages of engineered T cell therapies over traditional cancer treatments such as chemotherapy are expected to fuel their adoption in the analysis period. However, high cost of treatments and potential risk of engineered T cell treatments impede the growth of this market.

Request sample pdf brochure at:

Segmentation of Engineered T Cells Market

Segment Review

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into tumor infiltrating lymphocytes, T cell receptor {TCR}, and chimeric antigen receptor (CAR).

By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and others. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics.

By type, the chimeric antigen receptor cells accounts for highest revenue, due to increased applications of chimeric antigen receptor modified T cells in therapeutic research and advantages offered by CAR-T cells such as specificity of a targeted antibody and the ability to expand the T cell population. Moreover, rise in awareness towards CAR-T cell therapies and recent product approval of CAR-T cell treatment by the FDA boost the growth of the segment.

Increasing Prevalence of Cancer

According to WHO, cancer is one of the leading causes of death globally, and new cancer cases are anticipated to grow by about 60% in next few decades. As per the estimates given by the International Agency for Research on Cancer, there were 14.1 million cancer cases and 8.2 million cancer-related deaths globally in 2012.

As per the American Cancer Society, it was estimated that the global cancer burden is expected to increase to 21.7 million new cancer cases and 13 million deaths by 2030, owing to increase in geriatric population. Thus, increase in prevalence of cancer is expected to fuel the demand for novel therapeutic treatments in the future.

High Cost of Treatments

T cell therapies work by alteration of cellular DNA for prevention or treatment of diseases. The therapy development process is majorly labor intensive, and is tailored to specific patient rather than being developed for general population, making the treatment highly priced.

The procedure is meticulous and requires the viral vectors to cause minimal or no side effects after transfer. For instance, a recently approved gene therapy named Kymriah by Novartis costs around $475,000.

Furthermore, in future therapy to prevent blindness are projected to cost around $900,000 per patient. Therefore, high costs associated with T cell therapies impede growth of this market.

The major players operating in the global engineered T cells market are Autolus Limited, Bellicum Pharmaceuticals, Inc., Cells Medica, Elli Lilly and Company, Gilead Sciences, Inc., Juno Therapeutics, Novartis AG, Oxford Biomedica, Pfizer Inc., and Precision Bioscience.

Other players include Redmile Group LLC, Seeking Alpha, and Unum Therapeutics Inc

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the engineered T cells market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by type and application helps to understand various trends and prevailing opportunities in the respective market.
  • Comprehensive analysis of all geographical regions is provided, which determines the opportunities in these geographies.
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Engineered T Cells Market Key Segments: By Type

  • Tumor Infiltrating Lymphocytes
  • T Cell Receptor {TCR}
  • Chimeric Antigen Receptor (CAR)

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Leukemia
  • Others

By End User

  • Hospitals
  • Cancer Research Centers
  • Clinics

Do inquiry at:

News From

Allied Market Research - Powering Enterprises through Business IntelligenceAllied Market Research
Category: Market Research Publishers and RetailersCompany about: Allied Market Research is a global market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market dom ...
This email address is being protected from spambots. You need JavaScript enabled to view it.